Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Dec 7;12(1):600.
doi: 10.1186/s13287-021-02667-1.

Mesenchymal stem cell transplantation after acute myocardial infarction: a meta-analysis of clinical trials

Armin Attar  1 , Fateme Bahmanzadegan Jahromi  2 , Shahin Kavousi  2 , Ahmad Monabati  3   4 , Asma Kazemi  5
Affiliations
Meta-Analysis

Mesenchymal stem cell transplantation after acute myocardial infarction: a meta-analysis of clinical trials

Armin Attar et al. Stem Cell Res Ther. .

Abstract

Background: Trials investigating the role of mesenchymal stem cells (MSCs) in increasing ejection fraction (LVEF) after acute myocardial infarction (AMI) have raised some controversies. This study was conducted to find whether transplantation of MSCs after AMI can help improve myocardial performance indices or clinical outcomes.

Methods: Randomized trials which evaluated transplantation of MSCs after AMI were enrolled. The primary outcome was LVEF change. We also assessed the role of cell origin, cell number, transplantation time interval after AMI, and route of cell delivery on the primary outcome.

Results: Thirteen trials including 956 patients (468 and 488 in the intervention and control arms) were enrolled. After excluding the biased data, LVEF was significantly increased compared to the baseline among those who received MSC (WMD = 3.78%, 95% CI: 2.14 to 5.42, p < 0.001, I2 = 90.2%) with more pronounced effect if the transplantation occurred within the first week after AMI (MD = 5.74%, 95%CI: 4.297 to 7.183; I2 = 79.2% p < 0.001). The efficacy of trans-endocardial injection was similar to that of intracoronary infusion (4% [95%CI: 2.741 to 5.259, p < 0.001] vs. 3.565% [95%CI: 1.912 to 5.218, p < 0.001], respectively). MSC doses of lower and higher than 107 cells did not improve LVEF differently (5.24% [95%CI: 2.06 to 8.82, p = 0.001] vs. 3.19% [95%CI: 0.17 to 6.12, p = 0.04], respectively).

Conclusion: Transplantation of MSCs after AMI significantly increases LVEF, showing a higher efficacy if done in the first week. Further clinical studies should be conducted to investigate long-term clinical outcomes such as heart failure and cardiovascular mortality.

Keywords: Mesenchymal; Meta-analysis; Myocardial infarction; Stem cell.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
PRISMA flow diagram of the study
Fig. 2
Fig. 2
A Forest and funnel plot for ejection fraction before excluding the biased studies B forest plot for ejection fraction after excluding biased studies WMD weighted mean difference CI confidence interval
Fig. 3
Fig. 3
Subgroup analysis for the time interval between AMI and transplantation after excluding the biased studies WMD weighted mean difference CI confidence interval
Fig. 4
Fig. 4
Subgroup analysis for the route of delivery after excluding the biased studies
See this image and copyright information in PMC

References

    1. Organization WH. The global burden of disease: 2004 update. Geneva: World Health Organization; 2008.
    1. Velagaleti RS, Pencina MJ, Murabito JM, Wang TJ, Parikh NI, D'Agostino RB, et al. Long-term trends in the incidence of heart failure after myocardial infarction. Circulation. 2008;118(20):2057–2062. doi: 10.1161/CIRCULATIONAHA.108.784215. - DOI - PMC - PubMed
    1. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr, Colvin MM, et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016;134(13):e282–e293. - PubMed
    1. Lewis EF, Moye LA, Rouleau JL, Sacks FM, Arnold JM, Warnica JW, et al. Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. J Am Coll Cardiol. 2003;42(8):1446–1453. doi: 10.1016/S0735-1097(03)01057-X. - DOI - PubMed
    1. Juillière Y, Cambou JP, Bataille V, Mulak G, Galinier M, Gibelin P, et al. Heart failure in acute myocardial infarction: a comparison between patients with or without heart failure criteria from the FAST-MI registry. Revista Española de Cardiología (English Edition) 2012;65(4):326–333. doi: 10.1016/j.rec.2011.10.028. - DOI - PubMed

Publication types